Quickly consult our archives filtering by year :

 „Capture Deal Value – When and How?“

The 2019 Swiss Healthcare Licensing Group (HLG) Winter Conference focused on the topic “Capture Deal Value – When and How?”

The pharmaceutical industry is facing increasing challenges to cope with the quickly changing world economy. The requirements in healthcare are becoming ever more demanding considering the higher standard of data, financial investments and time, let alone governments` cost-containment measures getting more restrictive.

Both new and innovative molecules in the pipeline and growing access of patients to drug treatment especially in emerging markets are at the same time positive signals though. It seems that the pharmaceutical industry still finds room for creative ways to explore and implement new business models keeping pace with current changes in the healthcare environment.

Over three days, nearly 100 delegates from Switzerland, Europe, the US and Asia gathered in the Gruyère region to explore current and future innovative ways when and how to capture maximum deal value.

Conference Director, Ragip Ziyal with the active support of the entire Swiss HLG Board, gathered a global forum of high caliber speakers not only from the healthcare and consumer industry but also governmental initiatives to capture the maximum value for assets in the best manner and at the right time by (I) learning how synergies may be exploited for example during M&A transactions, (II) discussing the need for strategic access to new technologies and (III) looking at new players such as new public and public-private funding schemes as well as patient and non-profit organizations to support R&D funding.

Prior to the start of the conference, Marie Petit, Villiger Valuation Expert, and Partner orchestrated an interactive workshop to understand “Value of Sciences vs. Value of Cash” and so to decrypt the reasons behind using rNPV or VC methodologies to value projects or biotech companies.

In her opening keynote, Allison Jeynes-Ellis, CEO Avillion LLP, excellently set the scene by providing an innovative model on how the drug development, as well as the commercial risk, can be shared whereby Avillion is funding the clinical programme and receiving returns upon regulatory success and providing off-balance relief to the pharma partner.

The second day started with four distinct speakers exploring how synergies may be exploited in the pharmaceutical industry. Thomas Hafen, CEO Bühlmann Labs outlined the opportunities but also challenges when capturing value with point-of-care diagnostics.  Tim Schlange, Chief Marketing Officer at Lohmann Therapy Systems (LTS), followed with a focus on leveraging synergies between pharma and CDMO through innovative transdermal/-mucosal delivery technologies. Dominique Doyen, Director Business Development at 4SC underlined how partnerships can result in a business model at biotech along with Jochen Hurlebaus, Head of Central R&D Services, Innovation & IP at Roche Diagnostics who rather concentrated on accessing new technologies and thus securing value by getting access to digital innovation.

In a dynamic panel discussion, Ton Berkien, CBO at Nuevolution and former Head of M&A Emerging Markets at Takeda, Charles Hoare, Managing Director and Head of European Healthcare at Stiefel, Jordi Sabé, Founding Partner at Evolve Healthcare and former SVP Corporate Development at Almirall and Roberto Tracia, Partner at Oaklins Binder, all with a total of more than 80 years experience in international M&A transactions shared their view on synergies, which may be seen as one of the major motivators for M&A. They also discussed  key success factors and challenges during the integration of assets post-M&A.

The topic capturing value through the strategic access to new technologies dominated the second half of the second day. Sascha Bucher, VP and Head of Global Transactions at Roivant Sciences highlighted Roivant`s ecosystem built on entrepreneurial biotech companies, the so-called Vants, a unique approach to source talents and to deploy technology to strive for efficient R&D and commercialization. Matthias Essenpreis, CTO at Roche Diagnostics described the dependency on external innovation, Roche Diagnostics being as the global leader in in vitro diagnostics and how dedicated processes were established to cope with this very challenge.

After a full day of inspiring presentations and the panel discussion, the delegates enjoyed a typical Swiss Fondue Dinner in an authentic Swiss barn nearby. It was a perfect setting to network with peers and exchange personal and professional experiences.

The last day of the conference focused on innovative financing in the pharmaceutical industry, starting with David Hughes, Senior Global Programme Head at Novartis` Anti-Infectives Global Health Development Unit. David gave an overview of publicly-funded models like EU`s Innovative Medicines Initiative (IMI) or US Government`s Biomedical Advanced R&D Authority (BARDA) established to close gaps in some key disease areas targeting anti-microbial resistance and neglected tropical diseases. Marc Gitzinger, CEO at Bioversys focused in his speech on financing and deal-making in the antibiotic market, which seems a broken economic model where initiatives established both the so-called “Push” funding and “Pull” mechanisms to fix the economic model for novel antibiotics. Finally, Stefan Fischer, National Contact Point (NCP) at Euresearch stressed the importance of public bottom-up funding like the Horizon 2020 financing opportunities for innovative SMEs with game-changing and market-creating innovations and technologies.

The outstanding closing keynote, delivered by Ernst Hafen, Professor of Systems Genetics at ETH Zurich and the President of the Biopark Zurich-Schlieren, the value of citizen-controlled health data. Ernst thereby underlined that we have to regain control over our data thus our digital self-determination and reduce our dependency on multinational data companies, which may determine our faith in the future.

The Swiss HLG Board sincerely expresses its thanks to the presenters and the attendees for the lively discussions and interactions. Without them the success of the Winter Conference would not have been possible. Please find below some images from the conference. Please click on the image to view it in its entirety. (Please click on the image to view it in its entirety and or a slide show.)

Disruption or Evolution? Contemporary Trends in Pharma Business Development

The EPLC, together with this years’ hosts the PLCF, are pleased to welcome you to the romantic city of Paris for the XV IPLS from 18th – 20th September 2019. The IPLS event is a great opportunity for the healthcare deal-making community to come together to learn, discuss, network and partner.

Without question we live in interesting times, the 15th IPLS has been
designed to explore some of the more disruptive influences and opportunities in the life science industry today.

Early Booking Rate available until 26th April 2019!

Two days of informative presentations from industry leading speakers, peer to peer networking, one-to-one meeting opportunities and continuous personal development, all in the world’s most popular and dynamic city, Paris.

Conference Programme Includes:

Contemporary Trends in Pharma Business Development
Artificial Intelligence
Medical Cannabis
Evolution of Business Development Teams

Ageing, a New Field of Investigation & Investment
The Continuum of Ageing & Age-Related Diseases
Ageing Opportunities in Pharmaceuticals
New Therapeutic Advances

And much more, including 7 hours of dedicated one-to-one partnering
Full Programme & Event Website

XV International Pharma Licensing Symposium
Pullman Hotel Paris Centre – Bercy
Paris, France
Wednesday 18th to Friday 20th September 2019

Who Should Attend? Business Development Professionals, Managing
Directors, General Managers, Business Owners, Investors, Advisors,
Financial, Marketing& Regulatory Executives


LAST CHANCE TO REGISTER and secure a conference space! 

Book your hotel here!

There are several options available for hotel bookings within different price categories, but all are limited.




We are all interested in making deals and see more of these in the media; this is at least the „bread and butter“ for BD&L professionals and what they are measured against.

Main questions in this context are not only to explore creative deal structures on how to maximise the value of any asset. We are all focusing on and thus serving the shareholders

to achieve their goals but also when the right time is to harvest the asset value they invested in for many years.

During the Conference, we will shed light on how to capture the maximum value for a deal

in the best manner and at the right time. The conference shall have three streams:

• Learning how synergies may be exploited for example during M&A transactions.

• Discussing the need for strategic access to new technologies.

• Looking at new players such as new public and public-private funding schemes as well

as patient and non-profit to support R&D funding.

Join us on Sunday afternoon to be part of our exciting 2019 Winter Conference with high-caliber speakers covering interesting topics.

Explore our inspiring program which will be available on our conference website It will be updated regularly over the next few weeks with newly confirmed speakers their abstracts and bios.

Register now and secure a conference space as well as hotel booking. There are several options available for hotel bookings within different price categories, but all are limited.

We are looking forward to welcoming you at the 2019 Swiss HLG Winter Conference in the fascinating scenery of the Gruyère region. Let’s learn together how to best capture deal



This is a great new opportunity to attend an event for business development executives from Swiss and European pharma and biotech companies seeking to work with partners from China to expand into the Chinese market.

The European-Chinese Pharma Partnering Event 2018 offers insights into the rapidly evolving Chinese pharma and biotech industry, its established as well as emerging players and their strategy to expand their capabilities and portfolios. Join us for an exclusive opportunity to meet Chinese executives looking to partner with Western pharma and biotech companies. The focus of this dedicated partnering event is to help life sciences companies find strategic partners, market expansion and/or funding in China. The two-day program consists of two parts: the main conference with industry speakers and company presentations, and separate partnering meetings (by invitation only).
The European-Chinese Pharma Partnering Event 2018 may be just the beginning of your relationship with the surging Chinese pharma industry.

Friday, October 12th, 2018: Switzerland Innovation Park Basel Area, Gewerbestrasse 24, 4123 Allschwil, Switzerland

Register HERE! (limited to 60 seats)

European-Chinese Pharma Partnering 2018

Join us, become a member !

Join Swiss HLG
as a member


Keep up to date with the latest information by signing up to our newsletter

Why it's worth joining us !

Learn more about Swiss HLG
and our initiatives